Lilly (Eli) & Co. (LLY)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David A. Ricks
Employees:
38,680
LILLY CORPORATE CTR, DROP CODE 1112, INDIANAPOLIS, IN 46285
3172762000

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. It operates through the Human Pharmaceutical Products and Animal Health segments. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Data derived from most recent annual or quarterly report
Market Cap 233.762 Billion Shares Outstanding959.025 Million Avg 30-day Volume 2.521 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 275.87 / 127.03 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from LLY instead.

View recent insider trading info

Funds Holding LLY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LLY BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

TAI JACKSON P

  • Director
61,349 2021-10-18 13

ALVAREZ RALPH

  • Director
50,159 2021-10-18 11

JOHNSON KIMBERLY H

  • Director
354 2021-10-18 9

VAN NAARDEN JACOB SVP, CEO LOXOONC, PRES LLYONC

  • Officer
9,034 2021-09-05 1

LILLY ENDOWMENT INC

  • 10% Owner
108,248,610 2021-08-18 26

WEEMS ALONZO SVP, ERM & CECO

  • Officer
5,061 2021-06-27 1

RAU DIOGO SVP & CIDO

  • Officer
20,160 2021-06-01 2

HERNANDEZ EDGARDO SVP & PRES., MFG. OPERATIONS

  • Officer
16,013 2021-05-02 1

ZAKROWSKI DONALD A CHIEF ACCOUNTING OFFICER

  • Officer
7,648 2021-04-28 3

HAKIM ANAT SVP, GC & SECRETARY

  • Officer
12,364 2021-03-01 1

ASHKENAZI ANAT SVP & CFO

  • Officer
17,953 2021-02-09 2

FRY STEPHEN F SVP, HR & DIVERSITY

  • Officer
134,854 2021-02-08 2

RICKS DAVID A PRESIDENT & CEO

  • Officer
  • Director
447,175 2021-02-08 2

BARNES MELISSA S CHIEF ETH/CMPL OFCR & SVP, ERM

  • Officer
35,543 2021-02-08 3

ZULUETA ALFONSO G SVP & PRESIDENT, LILLY INT'L

  • Officer
61,614 2021-02-08 2

NORTON JOHNA SENIOR VP, GLOBAL QUALITY

  • Officer
28,737 2021-02-08 3

PUSEY LEIGH ANN SVP, CORP. AFFAIRS & COMM.

  • Officer
18,529 2021-02-08 2

O'NEILL MYLES SVP & PRES., MFG. OPERATIONS

  • Officer
82,923 2021-02-08 2

SMILEY JOSHUA L

  • FORMER OFFICER
No longer subject to file 2021-02-08 2

SHAH AARTI S. SVP & CIDO

  • Officer
34,595 2021-02-08 3

SKOVRONSKY DANIEL SVP, CSO, AND PRES. LRL

  • Officer
115,680 2021-02-08 1

WHITE ANNE E. SVP & PRES-LILLY ONCOLOGY

  • Officer
33,840 2021-02-08 1

JONSSON PATRIK SVP & PRESIDENT LILLY USA

  • Officer
31,103 2021-02-08 1

MASON MICHAEL B SR. VP & PRES., LILLY DIABETES

  • Officer
26,123 2021-02-08 1

YUFFA ILYA SVP AND PRES, LILLY BIO-MEDS

  • Officer
10,349 2021-02-08 1

SULZBERGER GABRIELLE

  • Director
0 2021-01-25 1

SEIFERT KATHI P

  • Director
77,038 2020-11-16 1

ESKEW MICHAEL L

  • Director
43,707 2020-11-16 1

FYRWALD J ERIK

  • Director
66,818 2020-11-16 1

LUCIANO JUAN R

  • Director
12,566 2020-11-16 1

BAICKER KATHERINE

  • Director
20,310 2020-11-16 1

KAELIN WILLIAM G JR

  • Director
18,730 2020-11-16 1

RUNGE MARSCHALL S

  • Director
14,279 2020-11-16 1

JACKSON JAMERE

  • Director
6,981 2020-11-16 1

WALKER KAREN

  • Director
4,209 2020-11-16 1

BERTOZZI CAROLYN R

  • Director
6,243 2020-11-16 1

HARRINGTON MICHAEL J SENIOR VP AND GENERAL COUNSEL

  • Officer
No longer subject to file 2020-01-02 0

SHAW CHRISTI SVP AND PRES., LILLY BIO-MEDS

  • Officer
0 2019-05-03 0

MARRAM ELLEN R

  • Director
No longer subject to file 2019-04-15 0

CONTERNO ENRIQUE A SVP&PRES, LILLYDIAB & LILLYUSA

  • Officer
138,121 2019-02-15 0

SIMMONS JEFFREY N SVP&PRES. ELANCO ANIMAL HEALTH

  • Officer
No longer subject to file 2018-12-31 0

MAHONY SUSAN SVP & PRES., LILLY ONCOLOGY

  • Officer
46,612 2018-04-13 0

LUNDBERG JAN M EVP,SCIENCE&TECH AND PRES. LRL

  • Officer
199,212 2018-02-09 0

RICE DERICA W EVP-GLOBAL SERVICES AND CFO

  • Officer
No longer subject to file 2017-12-31 0

CROWE MARIA A PRESIDENT, MFG. OPERATIONS

  • Officer
No longer subject to file 2017-12-31 0

HOOVER R DAVID

  • Director
37,784 2017-11-20 0

PRENDERGAST FRANKLYN G

  • Director
68,574 2017-11-20 0

LECHLEITER JOHN C

  • FORMER DIRECTOR
No longer subject to file 2017-05-04 0

PETERSON BARTON R SR. VP, CORP. AFFAIRS & COMM.

  • Officer
109,872 2017-02-01 0

WALSH FIONNUALA M SVP, GLOBAL QUALITY

  • Officer
109,501 2017-02-01 0

HORN KAREN N

  • Director
73,166 2015-11-30 0

OBERHELMAN DOUGLAS R

  • Director
22,675 2014-11-28 0

TAPIERO JACQUES SVP&PRES., EMERGING MARKETS

  • Officer
No longer subject to file 2014-01-28 0

BISCHOFF WINFRIED F W SIR

  • Director
42,444 2013-11-29 0

GILMAN ALFRED G

  • Director
48,287 2013-11-29 0

HANISH ARNOLD C CHIEF ACCOUNTING OFFICER

  • Officer
No longer subject to file 2012-08-29 0

ARMITAGE ROBERT A SR. VP AND GENERAL COUNSEL

  • Officer
134,132 2012-02-01 0

DEANE FRANK M PRESIDENT, MFG. OPERATIONS

  • Officer
36,514 2012-02-01 0

CARMINE BRYCE D. EVP AND PRES, LILLY BIO-MEDS

  • Officer
109,516 2012-02-01 0

NOBLES ANNE CHIEF ETH/CMPL OFCR & SVP, ERM

  • Officer
30,277 2012-01-26 0

FELDSTEIN MARTIN S

  • Director
30,733 2011-11-30 0

PAUL STEVEN M EVP, SCIENCE AND TECHNOLOGY

  • Officer
77,937 2010-02-01 0

SANTINI GINO SR.VP, CORP. STRATEGY & BD

  • Officer
No longer subject to file 2009-12-31 0

JOHNSON JOHN H SR. VP, ONCOLOGY BUSINESS UNIT

  • Officer
0 2009-11-01 0

MURPHY ANTHONY JOHN SENIOR VP, HUMAN RESOURCES

  • Officer
54,892 2009-02-02 0

CONNELLY DEIRDRE P PRESIDENT, U.S. OPERATIONS

  • Officer
0 2009-01-27 0

AZAR ALEX M II SR. VP, CORP. AFFAIRS & COMM.

  • Officer
0 2009-01-27 0

TAUREL SIDNEY CHAIRMAN

  • Officer
  • Director
No longer subject to file 2008-12-31 0

COOK J MICHAEL

  • Director
17,337 2008-11-28 0

FISHER GEORGE M C

  • Director
No longer subject to file 2008-04-30 0

TALLARIGO LORENZO PRESIDENT, INTERNAT'L OPERS.

  • Officer
66,611 2008-03-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

ALVAREZ RALPH - Director

2021-10-20 16:13:40 -0400 2021-10-18 A 46 $238.98 a 50,159 direct 1.0698 1.0698 2 0.0 1

JOHNSON KIMBERLY H - Director

2021-10-20 16:09:25 -0400 2021-10-18 A 40 $238.98 a 354 direct 1.0698 1.0698 2 0.0 1

TAI JACKSON P - Director

2021-10-20 16:06:50 -0400 2021-10-18 A 8 $238.98 a 61,349 direct 1.0698 1.0698 2 0.0 1

TAI JACKSON P - Director

2021-09-22 18:03:03 -0400 2021-09-20 A 9 $231.64 a 61,341 direct -0.2154 -0.4867 0.0 1 -4.5568 4

ALVAREZ RALPH - Director

2021-09-22 18:07:22 -0400 2021-09-20 A 47 $231.64 a 50,113 direct -0.2154 -0.4867 0.0 1 -4.5568 4

JOHNSON KIMBERLY H - Director

2021-09-22 18:04:52 -0400 2021-09-20 A 42 a 314 direct -0.2154 -0.4867 0.0 1 -4.5568 4

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ELI LILLY & CO LLY 2021-10-22 22:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 21:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 21:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 20:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 20:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 19:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 19:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 18:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 18:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 17:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 17:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 16:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 16:15:04 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 15:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 15:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 14:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 14:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 13:45:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 13:15:03 UTC -0.18 0.25 0
ELI LILLY & CO LLY 2021-10-22 12:45:03 UTC -0.18 0.25 0

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Absolute 500 Core Fund LLY -8.0 shares, $-1109.76 2020-03-31 N-PORT
FundVantage Trust- Gotham Master Neutral Fund LLY -2.0 shares, $-296.04 2020-09-30 N-PORT
FundVantage Trust- Gotham Neutral 500 Fund LLY -25.0 shares, $-4670.5 2021-03-31 N-PORT
FundVantage Trust- Gotham Enhanced 500 Plus Fund LLY -129.0 shares, $-29608.08 2021-06-30 N-PORT

Elevate your investments